Adaptive Biotechnologies Corp (Adaptive) is a developer of immune-driven medicine. Its products include immunoSEQ, T-Detect, Vaccines and clonoSEQ. The company provides an immune-sequencing platform to laboratories for conducting research in the areas of oncology and other immune-mediated diseases and TCR screening for the development of vaccines. Adaptive develops assays for both clinical diagnosis and therapeutic monitoring for a variety of disorders and conditions. It specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company translates immune-sequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. It partnered with institutions and biopharmaceutical companies. Adaptive is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
1165 Eastlake Ave East, Seattle, Washington, 98109
Website
www.adaptivebiotech.com
Telephone
1 206 6590067
No of Employees
709
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADPT (NASD)
Revenue (2022)
$170.3M
-8.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-12.5%
(2022 vs 2021)
Market Cap*
$354.0M
Net Profit Margin (2022)
XYZ
-22.5%
(2022 vs 2021)
* As of and is in US$
Adaptive Biotechnologies Corp premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| immunoSEQ | Drug Discovery |
| immunoSEQ T-MAP | Life Sciences Research |
| T-Detect | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ assay technology. |
| 2022 | Contracts/Agreements | In October, the company entered into a partnership with Epic to integrate the clonoSEQ Assay into Epic’s comprehensive electronic medical record system. |
| 2022 | Others | In February, the company announced new data demonstrating ImmunoSEQ Technology to identify T-cell receptors associated with crohn’s disease. |
Competitor Comparison
| Key Parameters | Adaptive Biotechnologies Corp | Illumina Inc | Natera Inc | 10X Genomics Inc | Krystal Biotech Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Seattle | San Diego | Austin | Pleasanton | Pittsburgh |
| State/Province | Washington | California | Texas | California | Pennsylvania |
| No. of Employees | 709 | 10,590 | 3,282 | 1,243 | 229 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chad Robins | Chief Executive Officer; Chairman | Executive Board | 2009 | 49 |
| Tycho Peterson | Chief Financial Officer | Senior Management | 2022 | 51 |
| Julie Rubinstein | President; Chief Operating Officer | Senior Management | 2018 | 52 |
| Francis Lo | Chief People Officer | Senior Management | 2019 | 43 |
| Harlan Robins, Ph.D. | Chief Scientific Officer | Senior Management | 2009 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward